Human Papillomavirus (HPV) Vaccine Archive
-- Superseded Information -- HISTORICAL USE ONLY -- See Current Information --VIS News - Update to Human Papillomavirus Vaccine Information Statements
May 5, 2011 -- The Bureau of Immunization wishes to announce the availability of the updated (interim) Human Papillomavirus (HPV) Vaccine Information Statements (VIS). An updated (interim) VIS was posted on May 4, 2011. Minor changes were made in these VISs to reflect the approval of quadrivalent HPV vaccine for prevention of anal cancer. Recommendations for the vaccines' use have not changed, and while use of the most recent VIS is always desirable, providers may use up stocks of existing HPV VISs.
VIS are information sheets produced by the Centers for Disease Control and Prevention (CDC) that explain to vaccine recipients, their parents, or their legal representatives both the benefits and risks of a vaccine. Federal law requires that VIS be handed out when (before each dose) certain vaccinations are given.
Print-ready files can be found on the CDC website at www.cdc.gov/vaccines/pubs/vis/default.htm#hpv.
These new VIS have been integrated into the Florida SHOTS™ (State Health Online Tracking System), so registry users can access them electronically. Healthcare providers should periodically access the VIS electronically and print out a supply for routine distribution. If necessary, bureau staff can FAX copies to providers without internet access.
Vaccine Information Statement Updates
April 12, 2010 -- The Bureau of Immunization is pleased to highlight recent updates to several vaccine information statements: measles-mumps-rubela-varicella (MMRV), human papillomavirus (HPV), and pneumococcal conjugate vaccine-13 (PCV13).
Quadrivalent Human Papillomavirus Vaccine Recommendations
The Bureau of Immunization is pleased to announce the release of the Morbidity and Mortality Weekly Report (MMWR) March 12, 2007, Volume 56, Early Release titled Quadrivalent Human Papillomavirus Vaccine, Recommendations of the Advisory Committee on Immunization Practices (ACIP).
These recommendations represent the first statement by the ACIP on the use of a quadrivalent human papillomavirus (HPV) vaccine licensed by the Food and Drug Administration (FDA) on June 8, 2006. This report summarizes the epidemiology of HPV and associated diseases, describes the licensed HPV vaccine, and provides recommendations for its use for vaccination among females 9 through 26 years of age in the U.S.
In June 2006, the quadrivalent HPV vaccine types 6, 11, 16, 18, under the trade name Gardasil® (manufactured by Merck and Co.), was licensed for use among females 9 through 26 years of age for prevention of HPV-type-related cervical cancer, cervical cancer precursors, vaginal and vulvar cancer precursors, and anogenital warts. The vaccine is administered by intramuscular injection, and the recommended schedule is a 3-dose series, with the second and third doses administered 2 and 6 months after the first dose. The recommended age for vaccination of females is 11 and 12 years of age. Vaccine can be administered as young as 9 years of age. Catch-up vaccination is recommended for females 13 through 26 years of age who have not been previously vaccinated. Vaccination is not a substitute for routine cervical cancer screening, and vaccinated females should have cervical cancer screening as recommended.
Please note: The information detailed in the HPV Vaccine Update correspondence dated February 16, 2007, regarding provision of HPV vaccine to VFC-eligible females by County Health Departments, is still effective.
Update to the ACIP recommendations regarding HPV vaccine that were distributed on December 1, 2006: As recommended by the ACIP, the bureau encourages all providers to routinely target HPV vaccine to all females 11 and 12 years of age. HPV vaccine should also be made available to all other eligible females.
The MMWR can be viewed online at
www.cdc.gov/mmwr/preview/mmwrhtml/rr56e312a1.htm
Update on Vaccines for Children Program Human Papillomavirus Vaccine Availability
The Bureau of Immunization is providing this important update to the Advisory Committee On Immunization Practices (ACIP) recommendations regarding human papillomavirus (HPV) vaccine that were distributed on December 1, 2006.
As recommended by the ACIP, the bureau encourages county health departments to target HPV vaccine to all females 11 and 12 years of age. However, state-supplied HPV vaccine should also be made available to VFC-eligible females 9 through 18 years of age who request the vaccine. Note: in those instances where insurance does not cover the HPV vaccine, children can obtain VFC vaccine free of charge at Federally Qualified Health Centers (FQHCs). As we monitor early vaccine uptake and inventory, providers may receive fewer doses than ordered.
Call the VFC Manager if you have questions regarding the VFC vaccine supply, and the Executive Community Health Nursing Director for questions regarding the vaccine recommendations at 850-245-4342.
Revised Human Papillomavirus Vaccine Information Statement
The revised human papillomavirus (HPV) Vaccine Information Statement (VIS) dated 2/2/07 has been released. On February 2, the Centers for Disease Control and Prevention (CDC) made a minor change to the interim VIS for HPV vaccine. Section 3 of the HPV VIS has been revised. Specifically, the VIS clarifies that the routine 3-dose schedule also applies to catch-up immunizations. The updated VIS is now available. Existing stocks of the previous (September 5, 2006) version may still be used. To access a ready-to-print (PDF) version of the updated (February 2, 2007) interim VIS, go to the CDC website at www.cdc.gov/vaccines/pubs/vis/default.htm#hpv or the IAC website at www.immunize.org/vis/hpv.pdf. Please widely distribute this VIS and vaccine information to colleagues, members, coalitions, and partners with an interest in the supply, distribution, management, and administration of human papillomavirus vaccine, and place this information on your website.
Please call the Bureau of Immunization if you have questions regarding the HPV VIS statement at 850-245-4342.
Provisional Recommendations for use of Quadrivalent Human Papillomavirus Vaccine
The Bureau of Immunization is pleased to announce the release of the Provisional Recommendations for use of quadrivalent human papillomavirus (HPV) vaccine by the Centers for Disease Control and Prevention (CDC) and the National Immunization Program (NIP). Please ensure that the Advisory Committee on Immunization Practices (ACIP) provisional recommendations are shared with colleagues, members, coalitions, and partners with an interest in the prevention of HPV infection and administration of HPV vaccine. The recommendations may be viewed at www.cdc.gov/.
The ACIP issued provisional recommendations that this vaccine be routinely administered to girls 11 and 12 years of age and used for catch-up immunization in females 13 through 26 years of age. Gardasi®, manufactured by Merck, is the first HPV vaccine approved by the Food and Drug Administration (FDA) to prevent cervical cancer. Gardasil is licensed as a 3-dose series, with dose number two given two months after dose number one, and dose number three given four months after dose number two. The minimum interval between doses number one and two is four weeks, and between doses number two and three is 12 weeks. The vaccine should be administered intramuscular (IM) in the deltoid. For more information on the use of HPV vaccine, see the recommendations.
Clinicians should be prepared to discuss prevention of HPV infection with their adolescent patients. The interim HPV Vaccine Information Statement (VIS) dated September 5, 2006 is found at www.cdc.gov/vaccines/pubs/vis/.
VISs are information sheets produced by the CDC that explain to vaccine recipients, their parents, or their legal representatives both the benefits and risks of a vaccine. Federal law requires that VISs be handed out (before each dose) whenever certain vaccinations are given.
ACIP recommendations do not become official until they are published in the CDC's Morbidity and Mortality Weekly Report (MMWR), which is expected to occur later this year. While no MMWR has been issued as yet, providers can begin using HPV vaccine with the provisional ACIP recommendation. Providers should also observe indications and contraindications, as listed in the manufacturer's package insert.
Important Vaccines for Children Program Information
Florida's Vaccines for Children (VFC) Program will provide human papillomavirus (HPV) vaccine effective December 4, 2006. Due to limited vaccine supply, VFC Program HPV vaccine is presently available only to Florida VFC-eligible female clients who are 11 and 12 years of age. At this time, there are no federal or state funds available to provide HPV vaccine to non-VFC-eligible clients who do not meet these criteria. Please note: Vaccine supply is based on product availability. This may result in County Health Departments receiving fewer doses of HPV vaccine than originally requested. The updated order form will be posted on the internet in time for December 4, 2006 orders.
Human Papillomavirus Vaccine Information Statement
The Bureau of Immunization is pleased to announce the release of the Human Papillomavirus (HPV) Vaccine Information Statement (VIS) dated September 5, 2006. Once a VIS is available, it should be used, effective immediately. The VIS can be viewed online at www.cdc.gov/vaccines/pubs/vis/.
While 3 doses of HPV vaccine are routinely recommended for girls 11 and 12 years of age, the vaccine is licensed for vaccination of girls and women 9 through 26 years of age.
Please note: The vaccine is not presently available through the Florida Vaccines for Children (VFC) Program. The VFC Program will notify providers when the vaccine is available for order. There are no plans at this time to add HPV to the Florida school entry requirement.
You may contact the VFC Coordinator if you have questions regarding the Human Papillomavirus VFC vaccine supply, and the Executive Community Health Nursing Director for questions regarding the vaccine recommendations at 850-245-4342.
